Table 4. Comparison of the clinical characteristics between survivors and non-survivors in the non-immunocompromised group.
| Variables | Survivors (n = 4) | Non-survivors (n = 10) | P |
|---|---|---|---|
| Mean age y (range) | 76.0 (37.5–80.7) | 74.0 (71.2–79.7) | 0.887 |
| Male | 3 (75.0%) | 3 (30.0%) | 0.245 |
| Hypertension | 1 (25.0%) | 3 (30.0%) | 1.000 |
| Diabetes | 0 (0%) | 2 (20.0%) | 1.000 |
| COPD | 0 (0%) | 1 (10.0%) | 1.000 |
| Cardiovascular disease | 3 (75.0%) | 4 (40.0%) | 0.559 |
| Interstitial lung disease | 0 (0%) | 3 (30.0%) | 0.505 |
| Chronic kidney disease | 2 (50.0%) | 1 (10.0%) | 0.176 |
| Chronic liver disease | 0 (0%) | 1 (10.0%) | 1.000 |
| Cough | 2 (50%) | 8 (80%) | 0.520 |
| Sputum | 1 (25%) | 5 (50%) | 0.580 |
| Fever | 2 (50%) | 4 (40%) | 1.000 |
| Dyspnea | 2 (50%) | 10 (100%) | 1.000 |
| BAL sample | 3 (75.0%) | 2 (20.0%) | 1.000 |
| WBC (*103/μL) | 12.0 (11.2–13.8) | 11.3 (7.1–15.8) | 0.777 |
| CRP (mg/dL) | 9.0 (4.8–13.5) | 14.2 (3.7–20.8) | 0.671 |
| LDH (U/L) | 908 (498–1332) | 1293 (870–1708) | 0.157 |
| Duration between admission and anti-PCP treatment, days | 6.0 (2.0–9.2) | 9.0 (2.0–10.0) | 0.825 |
| Glucocorticoids | 3 (75.0%) | 9 (90.0%) | 0.505 |
| Mechanical ventilator support | 2 (50.0%) | 7 (70%) | 0.580 |
| HFNC support | 2 (50.0%) | 3 (30%) | 0.580 |
Data are presented as median (interquartile range) or number (%). BAL, bronchoalveolar lavage; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; HFNC, high-flow nasal cannula; HIV, human immunodeficiency virus; IC, immunocompromised; LDH, lactate dehydrogenase; PCP, Pneumocystis jirovecii pneumonia; WBC, white blood cells.